| 周 越,苑珩珩,韩 宇.POLE/POLD1突变在肿瘤免疫治疗预后中的价值[J].中国肿瘤,2022,31(3):215-220. |
| POLE/POLD1突变在肿瘤免疫治疗预后中的价值 |
| Prognostic Value of POLE/POLD1 Mutation in Cancer Immunotherapy |
| 投稿时间：2021-10-30 |
| DOI：10.11735/j.issn.1004-0242.2022.03.A008 |
|
 |
| 中文关键词: POLE/POLD1 免疫治疗 生物标志物 肿瘤 |
| 英文关键词:POLE/POLD1 immunotherapy biomarkers cancer |
| 基金项目: |
|
| 摘要点击次数: 1144 |
| 全文下载次数: 191 |
| 中文摘要: |
| 摘 要：免疫检查点抑制剂（immune checkpoint inhibitors，ICIs）已在多种肿瘤中显示出持续的临床疗效。错配修复蛋白缺陷(mismatch repair deficient，dMMR）或微卫星高度不稳定性（microsatellite instability-high，MSI-H）的转移性结直肠癌患者已从免疫治疗中获益。然而，部分PD-L1阴性和微卫星稳定（microsatellite stability，MSS）型结直肠癌患者对免疫治疗也有持续的反应。因此，为了给患者制定最佳治疗方案，选择能够识别免疫检查点阻断疗效的可靠生物标志物，实现精准治疗是至关重要的。DNA聚合酶亚基的关键编码基因POLE/POLD1是除MSI?鄄H和肿瘤突变负荷（tumor mutation burden，TMB）外，最具潜力的免疫治疗预测指标。全文就POLE/POLD1的分子机制及其突变在免疫治疗中的研究进展进行综述。 |
| 英文摘要: |
| Abstract： Immunotherapy such as immune checkpoint inhibitors(ICIs) therapy have shown sustained clinical efficacy in a variety of tumor types. Patients with microsatellite instability-high/mismatch repair deficient(MSI-H/dMMR) may benefit from immunotherapy. However， some patients with negative PD-L1 or microsatellite stability(MSS) also have a sustained response to immunothe-rapy. Therefore， in order to achieve precision treatment for patients， it is critical to select reliable biomarkers for predicting the efficacy of immune checkpoint blocking. The key encoding gene of DNA polymerase subunit—POLE/POLD1 is one of the most promising predictors of immunotherapy， besides of MSI-H and tumor mutation burden. In this article， the molecular mechanism of POLE/POLD1 and its recent advances in immunotherapy are reviewed. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |